Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis

Brain and Behavior

Volumn 3, Issue 6, 2013, Pages 664-682

  Moore, Spencer ^a   Khalaj, Anna J ^a   Yoon, Jaehee ^a   Patel, Rhusheet ^a   Hannsun, Gemmy ^a   Yoo, Timothy ^a   Sasidhar, Manda ^a   Martinez Torres, Leonardo ^a   Hayardeny, Liat ^c   Tiwari Woodruff, Seema K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Pharmacology Unit   (Israel)

Author keywords

Axon conduction; Demyelination; Experimental autoimmune encephalomyelitis; Laquinimod; Multiple sclerosis; Myelination; Neuroprotective drug; Oligodendrocytes; Peripheral cytokines; Rotorod motor performance; Therapeutic treatment

Indexed keywords

CYTOKINE; GELATINASE B; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 5; INTERLEUKIN 6; LAQUINIMOD; MYELIN; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AXON REMYELINATION; CELL COUNT; CONTROLLED STUDY; CORPUS CALLOSUM; CYTOKINE PRODUCTION; DEMYELINATION; EARLY INTERVENTION; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOCHEMISTRY; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; MYELIN DEFICIENCY; NERVE CONDUCTION; NERVE CONDUCTION DISORDER; NERVE FIBER DEGENERATION; NERVE INJURY; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; RAT; REFRACTORY PERIOD; REMYELINIZATION; SPLEEN CELL; WHITE MATTER;

EID: 84893507025     PISSN: None     EISSN: 21623279     Source Type: Journal    
DOI: 10.1002/brb3.174     Document Type: Article

References (52)

1. Aharoni, R., R. Saada, R. Eilam, L. Hayardeny, M. Sela, and R. Arnon. 2012. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 251:14-24.
2. Bannerman, P. G., A. Hahn, S. Ramirez, M. Morley, C. Bonnemann, S. Yu, et al. 2005. Motor neuron pathology in experimental autoimmune encephalomyelitis: studies in THY1-YFP transgenic mice. Brain 128:1877-1886.
3. Bates, D. 2011. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology 76:S14-S25.
4. Boroojerdi, B., M. Hungs, M. Mull, R. Topper, and J. Noth. 1998. Interhemispheric inhibition in patients with multiple sclerosis. Electroencephalogr. Clin. Neurophysiol. 109:230-237.
5. Brambilla, R., T. Persaud, X. Hu, S. Karmally, V. I. Shestopalov, G. Dvoriantchikova, et al. 2009. Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation. J. Immunol. 182:2628-2640.
6. Brown, D. A., and P. E. Sawchenko. 2007. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J. Comp. Neurol. 502:236-260.
7. Bruck, W., R. Pfortner, T. Pham, J. Zhang, L. Hayardeny, V. Piryatinsky, et al. 2012. Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 124:411-424.
8. Brunmark, C., A. Runstrom, L. Ohlsson, B. Sparre, T. Brodin, M. Astrom, et al. 2002. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 130:163-172.
9. Chang, A., S. M. Staugaitis, R. Dutta, C. E. Batt, K. E. Easley, A. M. Chomyk, et al. 2012. Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann. Neurol. 76:918-926.
10. Comi, G., A. Pulizzi, M. Rovaris, O. Abramsky, T. Arbizu, A. Boiko, et al. 2008. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371:2085-2092.
11. Comi, G., D. Jeffery, L. Kappos, X. Montalban, A. Boyko, M. A. Rocca, et al. 2012. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 366:1000-1009.
12. Crawford, D. K., M. Mangiardi, and S. K. Tiwari-Woodruff. 2009a. Assaying the functional effects of demyelination and remyelination: revisiting field potential recordings. J. Neurosci. Methods 182:25-33.
13. Crawford, D. K., M. Mangiardi, X. Xia, H. E. Lopez-Valdes, and S. K. Tiwari-Woodruff. 2009b. Functional recovery of callosal axons following demyelination: a critical window. Neuroscience 164:1407-1421.
14. Crawford, D. K., M. Mangiardi, B. Song, R. Patel, S. Du, M. V. Sofroniew, et al. 2010. Oestrogen receptor {beta} ligand: a novel treatment to enhance endogenous functional remyelination. Brain 133:2999-3016.
15. De Stefano, N., P. M. Matthews, M. Filippi, F. Agosta, M. De Luca, M. L. Bartolozzi, et al. 2003. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 60:1157-1162.
16. Dutta, R., and B. D. Trapp. 2011. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog. Neurobiol. 93:1-12.
17. Eng, L. F. 1985. Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J. Neuroimmunol. 8:203-214.
18. Feng, G., R. H. Mellor, M. Bernstein, C. Keller-Peck, Q. T. Nguyen, M. Wallace, et al. 2000. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 28:41-51.
19. Franklin K., and G. Paxinos. 2001. The mouse brain: in stereotaxic coordinates. Academic Press, San Diego, CA.
20. Gasperini, C., and S. Ruggieri. 2009. New oral drugs for multiple sclerosis. Neurol. Sci. 30(Suppl 2):S179-S183.
21. Gurevich, M., T. Gritzman, R. Orbach, T. Tuller, A. Feldman, and A. Achiron. 2010. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J. Neuroimmunol. 221:87-94.
22. Hetman, M., K. Kanning, J. E. Cavanaugh, and Z. Xia. 1999. Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. J. Biol. Chem. 274:22569-22580.
23. Hobom, M., M. K. Storch, R. Weissert, K. Maier, A. Radhakrishnan, B. Kramer, et al. 2004. Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol. 14:148-157.
24. Jones, M. V., T. T. Nguyen, C. A. Deboy, J. W. Griffin, K. A. Whartenby, D. A. Kerr, et al. 2008. Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis. J. Neuroimmunol. 199:83-93.
25. Kumar, S., R. Patel, S. Moore, D. K. Crawford, N. Suwanna, M. Mangiardi, et al. 2013. Estrogen receptor beta ligand therapy activates PI3K/Akt/mTOR signaling in oligodendrocytes and promotes remyelination in a mouse model of multiple sclerosis. Neurobiol. Dis. 56:131-144.
26. Liedtke, W., W. Edelmann, F. C. Chiu, R. Kucherlapati, and C. S. Raine. 1998. Experimental autoimmune encephalomyelitis in mice lacking glial fibrillary acidic protein is characterized by a more severe clinical course and an infiltrative central nervous system lesion. Am. J. Pathol. 152:251-259.
27. Linker, R., R. Gold, and F. Luhder. 2009. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit. Rev. Immunol. 29:43-68.
28. Linker, R. A., D. H. Lee, S. Demir, S. Wiese, N. Kruse, I. Siglienti, et al. 2010. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 133:2248-2263.
29. MacKenzie-Graham, A., S. K. Tiwari-Woodruff, G. Sharma, C. Aguilar, K. T. Vo, L. V. Strickland, et al. 2009. Purkinje cell loss in experimental autoimmune encephalomyelitis. Neuroimage 48:637-651.
30. Mallon, B. S., H. E. Shick, G. J. Kidd, and W. B. Macklin. 2002. Proteolipid promoter activity distinguishes two populations of NG2-positive cells throughout neonatal cortical development. J. Neurosci. 22:876-885.
31. Mangiardi, M., D. K. Crawford, X. Xia, S. Du, R. Simon-Freeman, R. R. Voskuhl, et al. 2011. An animal model of cortical and callosal pathology in multiple sclerosis. Brain Pathol. 21:263-278.
32. Numakawa, T., S. Suzuki, E. Kumamaru, N. Adachi, M. Richards, and H. Kunugi. 2010. BDNF function and intracellular signaling in neurons. Histol. Histopathol. 25:237-258.
33. Ozturk, A., S. A. Smith, E. M. Gordon-Lipkin, D. M. Harrison, N. Shiee, D. L. Pham, et al. 2010. MRI of the corpus callosum in multiple sclerosis: association with disability. Mult. Scler. 16:166-177.
34. Polman, C., F. Barkhof, M. Sandberg-Wollheim, A. Linde, O. Nordle, and T. Nederman. 2005. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64:987-991.
35. Rasmussen, S., Y. Wang, P. Kivisakk, R. T. Bronson, M. Meyer, J. Imitola, et al. 2007. Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing-remitting experimental autoimmune encephalomyelitis. Brain 130:2816-2829.
36. Reeves, T. M., L. L. Phillips, and J. T. Povlishock. 2005. Myelinated and unmyelinated axons of the corpus callosum differ in vulnerability and functional recovery following traumatic brain injury. Exp. Neurol. 196:126-137.
37. Ruffini, F., S. Rossi, A. Bergamaschi, E. Brambilla, A. Finardi, C. Motta, et al. 2012. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. Mult. Scler. 19:1084-1094.
38. Singer, W. 1995. Development and plasticity of cortical processing architectures. Science 270:758-764.
39. Steinman, L., and S. S. Zamvil. 2006. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 60:12-21.
40. Thone, J., G. Ellrichmann, S. Seubert, I. Peruga, D. H. Lee, R. Conrad, et al. 2012. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am. J. Pathol. 180:267-274.
41. Tiwari-Woodruff, S., L. B. Morales, R. Lee, and R. R. Voskuhl. 2007. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment. Proc. Natl. Acad. Sci. USA 104:14813-14818.
42. Vogt, J., F. Paul, O. Aktas, K. Muller-Wielsch, J. Dorr, S. Dorr, et al. 2009. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann. Neurol. 66:310-322.
43. Vondran, M. W., P. Clinton-Luke, J. Z. Honeywell, and C. F. Dreyfus. 2010. BDNF+/- mice exhibit deficits in oligodendrocyte lineage cells of the basal forebrain. Glia 58:848-856.
44. VonDran, M. W., H. Singh, J. Z. Honeywell, and C. F. Dreyfus. 2011. Levels of BDNF impact oligodendrocyte lineage cells following a cuprizone lesion. J. Neurosci. 31:14182-14190.
45. Warlop, N. P., E. Achten, J. Debruyne, and G. Vingerhoets. 2008a. Diffusion weighted callosal integrity reflects interhemispheric communication efficiency in multiple sclerosis. Neuropsychologia 46:2258-2264.
46. Warlop, N. P., E. Fieremans, E. Achten, J. Debruyne, and G. Vingerhoets. 2008b. Callosal function in MS patients with mild and severe callosal damage as reflected by diffusion tensor imaging. Brain Res. 1226:218-225.
47. Wegner, C., C. Stadelmann, R. Pfortner, E. Raymond, S. Feigelson, R. Alon, et al. 2010. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 227:133-143.
48. Wensky, A. K., G. C. Furtado, M. C. Marcondes, S. Chen, D. Manfra, S. A. Lira, et al. 2005. IFN-gamma determines distinct clinical outcomes in autoimmune encephalomyelitis. J. Immunol. 174:1416-1423.
49. Wu, E., and C. S. Raine. 1992. Multiple sclerosis. Interactions between oligodendrocytes and hypertrophic astrocytes and their occurrence in other, nondemyelinating conditions. Lab. Invest. 67:88-99.
50. Xiao, J., A. W. Wong, M. M. Willingham, M. van den Buuse, T. J. Kilpatrick, and S. S. Murray. 2010. Brain-derived neurotrophic factor promotes central nervous system myelination via a direct effect upon oligodendrocytes. Neurosignals 18:186-202.
51. Yang, J. S., L. Y. Xu, B. G. Xiao, G. Hedlund, and H. Link. 2004. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol. 156:3-9.
52. Ziehn, M. O., A. A. Avedisian, S. Tiwari-Woodruff, and R. R. Voskuhl. 2010. Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE. Lab. Invest. 90:774-786.